Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23674861 | 0.93 | AR (0.54) | ARHDAC1 | |
| SCHEMBL23674929 | 0.89 | AR (0.61) | ARPGRHDAC3HDAC4HDAC1 | |
| SCHEMBL23674781 | 0.84 | AR (0.53) | ARPGR | |
| SCHEMBL23692022 | 0.84 | AR (0.40) | ARPGRHDAC3HDAC4HDAC1 | |
| SCHEMBL16845463 | 0.84 | PGR (0.58) | ARPGR | |
| SCHEMBL23691999 | 0.83 | AR (0.61) | ARPGR | |
| SCHEMBL23674938 | 0.82 | AR (0.57) | ARHDAC1 | |
| SCHEMBL26449089 | 0.81 | PGR (0.53) | ARPGR | |
| SCHEMBL7785957 | 0.80 | AR (0.66) | ARPGR | |
| SCHEMBL16845631 | 0.80 | AR (0.65) | ARPGRHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135524-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135524-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135524-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021150603-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021150603-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135524-A1 | ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE | CYP21A2, AR, NR5A1 | AR 2/4885PGR 118/4885HDAC3 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.